
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2511978/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. New England Journal of Medicine, 2013, 369, 111-121.	27.0	1,284
2	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2018, 131, 1275-1291.	1.4	796
3	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematology,the, 2020, 7, e737-e745.	4.6	430
4	Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood, 2003, 101, 2125-2131.	1.4	309
5	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2021, 138, 2753-2767.	1.4	305
6	Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. Journal of Clinical Oncology, 2016, 34, 972-979.	1.6	296
7	Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood, 2012, 119, 332-341.	1.4	246
8	Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood, 2001, 98, 2633-2639.	1.4	242
9	Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management. Thrombosis and Haemostasis, 2008, 99, 4-13.	3.4	239
10	Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood, 2000, 96, 3948-3952.	1.4	225
11	Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood, 2004, 104, 1995-1999.	1.4	225
12	Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood, 2006, 108, 853-861.	1.4	171
13	Toward Optimization of Postremission Therapy for Residual Disease–Positive Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2008, 26, 4944-4951.	1.6	165
14	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood, 2019, 134, 935-945.	1.4	148
15	High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. Journal of Clinical Oncology, 2014, 32, 219-228.	1.6	145
16	Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood, 2010, 116, 2295-2303.	1.4	126
17	Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia. Cancer Research, 2006, 66, 8903-8911.	0.9	125
18	Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database. Journal of Clinical Oncology, 2013, 31, 2671-2677.	1.6	121

#	Article	IF	CITATIONS
19	The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia, 2006, 20, 1783-1789.	7.2	117
20	Azacitidine for the treatment of patients with acute myeloid leukemia. Cancer, 2012, 118, 1014-1022.	4.1	107
21	Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia, 2013, 27, 997-999.	7.2	101
22	Azacitidine for the treatment of lower risk myelodysplastic syndromes. Cancer, 2010, 116, 1485-1494.	4.1	98
23	MRD in AML: The Role of New Techniques. Frontiers in Oncology, 2019, 9, 655.	2.8	93
24	Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with Bâ€cell chronic lymphocytic leukemia. Cancer, 2008, 112, 119-128.	4.1	86
25	Acute megakaryoblastic leukemia: experience of GIMEMA trials. Leukemia, 2002, 16, 1622-1626.	7.2	81
26	Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17). Journal of Clinical Oncology, 2013, 31, 4424-4430.	1.6	78
27	Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genetics and Cytogenetics, 1993, 67, 28-34.	1.0	77
28	Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica, 2007, 92, 605-611.	3.5	76
29	Minimally Differentiated Acute Myeloid Leukemia (AML-M0): Comparison of 25 Cases With Other French-American-British Subtypes. Blood, 1997, 89, 621-629.	1.4	75
30	Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Annals of Oncology, 2012, 23, 1499-1502.	1.2	68
31	Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia, 2003, 17, 2178-2182.	7.2	67
32	Deregulation of the Mitochondrial Apoptotic Machinery and Development of Molecular Targeted Drugs in Acute Myeloid Leukemia. Current Cancer Drug Targets, 2008, 8, 207-222.	1.6	66
33	A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies <i>FLT3</i> -Mutated Clones in Acute Myeloid Leukemia. Clinical Cancer Research, 2015, 21, 3977-3985.	7.0	66
34	Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Annals of Oncology, 2011, 22, 1628-1635.	1.2	65
35	Temsirolimus, an mTOR inhibitor, in combination with lowerâ€dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AMLâ€1107). British Journal of Haematology, 2012, 156, 205-212.	2.5	65
36	Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica, 2015, 100, 284-292.	3.5	64

#	Article	IF	CITATIONS
37	Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood, 2000, 96, 3948-3952.	1.4	60
38	COVIDâ€19 elicits an impaired antibody response against SARSâ€CoVâ€2 in patients with haematological malignancies. British Journal of Haematology, 2021, 195, 371-377.	2.5	56
39	Risk-Adapted, MRD-Refined Therapeutic Approach for the Treatment of Acute Myeloid Leukemia: From a Single Center Experience to the Cooperative Gimema Protocol AML1310. Blood, 2012, 120, 1422-1422.	1.4	54
40	Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia, 2005, 19, 1840-1841.	7.2	53
41	BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 462-472.	3.8	53
42	Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. Haematologica, 2016, 101, 77-85.	3.5	53
43	Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treatment Reviews, 2008, 34, 49-60.	7.7	52
44	Randomized trial of two schedules of lowâ€dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AMLâ€19). British Journal of Haematology, 2010, 149, 376-382.	2.5	52
45	NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma. Frontiers in Medicine, 2015, 2, 33.	2.6	51
46	CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014075.	1.3	50
47	Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. Leukemia Research, 2015, 39, 296-306.	0.8	50
48	Chromosomal Aberration of the 11q23 Locus in Acute Leukemia and Frequency of <i>MLL</i> Gene Translocation. American Journal of Clinical Pathology, 2004, 122, 298-306.	0.7	49
49	Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. Leukemia, 2021, 35, 1529-1538.	7.2	48
50	Minimally differentiated acute myeloid leukaemia (AML-MO): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases. British Journal of Haematology, 1994, 88, 784-793.	2.5	46
51	The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer, 2005, 104, 2743-2752.	4.1	45
52	A cluster of <i>Geotrichum clavatum</i> (<i>Saprochaete clavata</i>) infection in haematological patients: a first Italian report and review of literature. Mycoses, 2016, 59, 594-601.	4.0	44
53	CD7 Expression in Acute Myeloid Leukemia. Leukemia and Lymphoma, 1995, 17, 111-119.	1.3	43
54	Clinical implications of cytokine and soluble receptor measurements in patients with newlyâ€diagnosed aggressive nonâ€Hodgkin's lymphoma. European Journal of Haematology, 1995, 54, 9-17.	2.2	41

#	Article	IF	CITATIONS
55	Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. Thrombosis Research, 2013, 132, 511-514.	1.7	41
56	FCÎ ³ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance. Frontiers in Immunology, 2017, 8, 457.	4.8	41
57	A Comparative Analysis of FISH, RT-PCR, and Cytogenetics for the Diagnosis of <i>bcr-abl</i> Positive Leukemias. American Journal of Clinical Pathology, 1998, 109, 24-31.	0.7	39
58	Identification of emerging <i><scp>FLT</scp>3 </i> <scp>ITD</scp> â€positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin. British Journal of Haematology, 2013, 161, 533-540.	2.5	39
59	Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. Seminars in Hematology, 2018, 55, 209-214.	3.4	39
60	Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness. Cancers, 2020, 12, 120.	3.7	39
61	Intensive treatment of patients age 60 years and older with De novo acute myeloid leukemia: Analysis of prognostic factors. , 1996, 77, 2476-2488.		38
62	Thrombosis in adult patients with acute leukemia. Current Opinion in Oncology, 2017, 29, 448-454.	2.4	38
63	An Allele-Specific RT-PCR Assay to Detect Type A Mutation of the Nucleophosmin-1 Gene in Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2008, 10, 212-216.	2.8	36
64	Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm. Haematologica, 2009, 94, 285-288.	3.5	36
65	A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias. Blood, 2010, 116, 2096-2102.	1.4	35
66	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. HemaSphere, 2022, 6, e676.	2.7	35
67	O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro. Pharmacological Research, 2006, 53, 317-323.	7.1	34
68	P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. Leukemia Research, 1999, 23, 451-465.	0.8	33
69	Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. Leukemia Research, 2014, 38, 469-474.	0.8	33
70	P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia. British Journal of Haematology, 2003, 121, 730-738.	2.5	32
71	CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. Haematologica, 2012, 97, 279-287.	3.5	32
72	Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a realâ€world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. European Journal of Haematology, 2016, 96, 344-351.	2.2	31

#	Article	IF	CITATIONS
73	Chromosomal Aberration of the 11q23 Locus in Acute Leukemia and Frequency of MLL Gene Translocation Results in 378 Adult Patients. American Journal of Clinical Pathology, 2004, 122, 298-306.	0.7	31
74	High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma. Annals of Hematology, 2014, 93, 1509-1513.	1.8	30
75	Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. Annals of Hematology, 2015, 94, 1319-1326.	1.8	30
76	<i>In vitro</i> elimination of epidermal growth factor receptorâ€overexpressing cancer cells by CD32Aâ€chimeric receptor T cells in combination with cetuximab or panitumumab. International Journal of Cancer, 2020, 146, 236-247.	5.1	30
77	P-Glycoprotein Expression in De Novo Acute Myeloid Leukemia. Leukemia and Lymphoma, 1997, 27, 257-274.	1.3	29
78	Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia, 2006, 20, 404-409.	7.2	28
79	A prognostic model for patients with lymphoma and COVID-19: aÂmulticentre cohort study. Blood Advances, 2022, 6, 327-338.	5.2	28
80	Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis. Annals of Hematology, 1996, 72, 208-215.	1.8	27
81	Comparison between conventional banding analysis and FISH screening with an AML-specific set of probes in 260 patients. The Hematology Journal, 2003, 4, 263-270.	1.4	27
82	CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias*. British Journal of Haematology, 2004, 125, 203-212.	2.5	26
83	Elacytarabine has singleâ€agent activity in patients â€~with advanced acute myeloid leukaemia. British Journal of Haematology, 2012, 158, 581-588.	2.5	26
84	Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use. Journal of Chemotherapy, 2017, 29, 131-143.	1.5	26
85	In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts. Annals of Hematology, 1997, 75, 145-147.	1.8	25
86	Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. American Journal of Hematology, 2019, 94, 1091-1097.	4.1	25
87	The emerging role of measurable residual disease detection in AML in morphologic remission. Seminars in Hematology, 2019, 56, 125-130.	3.4	25
88	Monitoring of minimal residual disease in acute myeloid leukemia. Current Opinion in Oncology, 2009, 21, 582-588.	2.4	24
89	Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients. Expert Review of Hematology, 2013, 6, 767-784.	2.2	23
90	Ironâ€chelating therapy with deferasirox in transfusionâ€dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. British Journal of Haematology, 2017, 177, 741-750.	2.5	23

#	Article	IF	CITATIONS
91	Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). Leukemia and Lymphoma, 2018, 59, 1113-1120.	1.3	23
92	Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. Journal of Hematology and Oncology, 2020, 13, 137.	17.0	23
93	GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Longâ€ŧerm results and prognostic factors. British Journal of Haematology, 2011, 154, 564-568.	2.5	22
94	Deferasirox chelation therapy in patients with transfusionâ€dependent <scp>MDS</scp> : a â€realâ€world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata. European Journal of Haematology, 2015, 95, 52-56.	2.2	22
95	Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia. Cancers, 2018, 10, 215.	3.7	22
96	Clinical Relevance of Minimal Residual Disease Detection in Adult Acute Myeloid Leukemia. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 349-357.	1.8	21
97	A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Hematological Oncology, 2013, 31, 117-126.	1.7	21
98	Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. Bone Marrow Transplantation, 2017, 52, 473-475.	2.4	21
99	Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia. Expert Review of Hematology, 2018, 11, 307-313.	2.2	21
100	Novel Agents for Acute Myeloid Leukemia. Cancers, 2018, 10, 429.	3.7	21
101	Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia. Haematologica, 2004, 89, 934-9.	3.5	20
102	Apoptosis and immaturity in acute myeloid leukemia. Hematology, 2005, 10, 25-34.	1.5	19
103	Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data. Journal of Chemotherapy, 2015, 27, 1-12.	1.5	19
104	Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia. DNA Repair, 2007, 6, 1179-1186.	2.8	18
105	M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. Haematologica, 2008, 93, 1025-1032.	3.5	18
106	MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016052.	1.3	18
107	Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies. Value in Health, 2019, 22, 1303-1310.	0.3	18
108	Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. Drugs of Today, 2016, 52, 249.	1.1	18

#	Article	IF	CITATIONS
109	Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. Haematologica, 2004, 89, 1468-75.	3.5	18
110	Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. Leukemia Research and Treatment, 2013, 2013, 1-6.	2.0	17
111	Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinicoâ€biological parameters. British Journal of Haematology, 2021, 193, 129-132.	2.5	17
112	Epidemiology of acute promyelocytic leukemia in Italy. Annals of Oncology, 1991, 2, 405-408.	1.2	16
113	Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr. European Journal of Haematology, 2002, 69, 200-204.	2.2	16
114	Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. Leukemia and Lymphoma, 2010, 51, 95-106.	1.3	16
115	Emerging strategies for the treatment of older patients with acute myeloid leukemia. Annals of Hematology, 2016, 95, 1583-1593.	1.8	16
116	Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia. Leukemia, 2019, 33, 1527-1530.	7.2	16
117	Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group. British Journal of Haematology, 2000, 111, 334-337.	2.5	16
118	The genotype nucleophosmin mutated and <i>FLT3</i> â€ITD negative is characterized by high bax/bclâ€2 ratio and favourable outcome in acute myeloid leukaemia. British Journal of Haematology, 2010, 149, 383-387.	2.5	15
119	Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia. Annals of Hematology, 2018, 97, 1767-1774.	1.8	15
120	Enhancement of anti-leukemia activity of NK cells <i>in vitro</i> and <i>in vivo</i> by inhibition of leukemia cell-induced NK cell damage. Oncotarget, 2016, 7, 2070-2079.	1.8	15
121	High-dose chemotherapy in adult acute myeloid leukemia: Rationale and results. Leukemia Research, 1996, 20, 535-549.	0.8	14
122	A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype. Leukemia Research, 1997, 21, 575-580.	0.8	14
123	Biological Features of Acute Myeloid Leukemia in the Elderly. Blood, 1998, 92, 697-699.	1.4	14
124	Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the <scp>SEIFEM</scp> â€D registry. British Journal of Haematology, 2015, 170, 434-439.	2.5	14
125	Applications and efficiency of flow cytometry for leukemia diagnostics. Expert Review of Molecular Diagnostics, 2019, 19, 1089-1097.	3.1	14
126	Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management. Medical Mycology, 2019, 57, S127-S137.	0.7	14

#	Article	IF	CITATIONS
127	Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network. Haematologica, 2020, 106, 39-45.	3.5	14
128	Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?. Leukemia, 2020, 34, 963-965.	7.2	14
129	New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia. Leukemia Research, 2001, 25, 349-351.	0.8	13
130	Mini-extracorporeal circulation minimizes coagulation abnormalities and ameliorates pulmonary outcome in coronary artery bypass grafting surgery. Perfusion (United Kingdom), 2013, 28, 298-305.	1.0	13
131	Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis. American Journal of Hematology, 2010, 85, 380-383.	4.1	12
132	Minimal residual disease as biomarker for optimal biologic dosing of <scp>ARA</scp> â€ <scp>C</scp> in patients with acute myeloid leukemia. American Journal of Hematology, 2015, 90, 125-131.	4.1	12
133	Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype. Haematologica, 2019, 104, 1168-1175.	3.5	12
134	Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies. Quality of Life Research, 2020, 29, 815-823.	3.1	12
135	Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23+ /mll + translocation in leukaemia. British Journal of Haematology, 2003, 121, 953-955.	2.5	11
136	Multidimensional Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia. Leukemia and Lymphoma, 2003, 44, 445-450.	1.3	11
137	â€ ⁻ Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. Journal of Antimicrobial Chemotherapy, 2019, 74, 1062-1068.	3.0	11
138	Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study. Blood, 2020, 136, 51-53.	1.4	10
139	Long Term Follow-Up of the Gimema GSI 103 AMLE Randomized Trial: Daunoxome Seems To Improve Disease-Free Survival (DFS) of Elderly Patients with Acute Myelogenous Leukemia (AML) Blood, 2006, 108, 1979-1979.	1.4	10
140	Contribution of immunophenotypic and genotypic analyses to the diagnosis of acute leukemia. Annals of Hematology, 1995, 71, 13-27.	1.8	9
141	Trisomy 4 as the sole karyotypic anomaly in acute biphenotypic leukemia with B lineage markers and in acute minimally differentiated myeloid leukemia (MO). Cancer Genetics and Cytogenetics, 1995, 80, 66-67.	1.0	9
142	Biological Pattern of AML-M0 Versus AML-M1: Response. Blood, 1997, 89, 345-345.	1.4	9
143	Two Novel Methods for Rapid Detection and Quantification of DNMT3A R882 Mutations in AcuteÂMyeloid Leukemia. Journal of Molecular Diagnostics, 2015, 17, 179-184.	2.8	9
144	Extensive toxic epidermal necrolysis following brentuximab vedotin administration. Annals of Hematology, 2015, 94, 355-356.	1.8	9

#	Article	IF	CITATIONS
145	Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage. Journal of Translational Medicine, 2016, 14, 239.	4.4	9
146	Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells. Blood Cancer Journal, 2020, 10, 85.	6.2	9
147	Mutational profile of ZBTB16â€RARAâ€positive acute myeloid leukemia. Cancer Medicine, 2021, 10, 3839-3847.	2.8	9
148	Targeting and Depletion of Acute Myeloid Leukemia Blasts By MEN1112, a Novel Humanized Defucosylated Monoclonal Antibodies with Specificity for Bst1/CD157 Antigen. Blood, 2014, 124, 2235-2235.	1.4	9
149	Improved Overall Survival with Gemtuzumab Ozogamicin (GO) Compared with Best Supportive Care (BSC) in Elderly Patients with Untreated Acute Myeloid Leukemia (AML) Not Considered Fit for Intensive Chemotherapy: Final Results from the Randomized Phase III Study (AML-19) of the EORTC and Gimema Leukemia Groups. Blood. 2014. 124. 619-619.	1.4	9
150	Prognostic Value of Cytogenetics and Multidrug Resistance (MDR1) in Elderly Patients With Acute Myeloid Leukemia. Blood, 1998, 92, 695-697.	1.4	9
151	Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia. Cancers, 2021, 13, 6246.	3.7	9
152	High interleukin-6 plasma levels in acute promyelocytic leukemia. Annals of Hematology, 1992, 64, 303-304.	1.8	8
153	All-trans retinoic acid plus low doses of cytarabine for the treatment of "poor-risk―acute myeloid leukemias. Annals of Hematology, 1993, 66, 59-60.	1.8	8
154	Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party. Hematological Oncology, 2008, 26, 104-107.	1.7	8
155	Simultaneous Occurrence of Monoclonal Gammopathy and Acute Secondary Leukemia with Overexpression of P-Glycoprotein. Tumori, 1992, 78, 403-406.	1.1	7
156	Recombinant Interferon α2a, Thymopentin and Low Doses of Cytosine Arabinoside for the Treatment of Myelodysplastic Syndromes: A Pilot Study. Leukemia and Lymphoma, 1995, 16, 335-342.	1.3	7
157	Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors. Transfusion and Apheresis Science, 2002, 26, 103-110.	1.0	7
158	Evaluation of the prognostic relevance of <scp>l</scp> â€selectin and ICAM1 expression in myelodysplastic syndromes. European Journal of Haematology, 2008, 80, 107-114.	2.2	7
159	Thoracic Cord Compression Caused by Epidural Extramedullary Hematopoiesis During Erythroid-Stimulating Agent Therapy in Two Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology, 2013, 31, e189-e191.	1.6	7
160	Recurrence of a t(8;21)-Positive Acute Myeloid Leukemia in the Form of a Granulocytic Sarcoma Involving Cranial Bones: A Diagnostic and Therapeutic Challenge. Case Reports in Hematology, 2013, 2013, 1-5.	0.4	7
161	Allâ€trans retinoic acid (ATRA) in nonâ€promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with lowâ€dose Araâ€C in three elderly patients with NPM1 â€mutated AML unfit for intensive chemotherapy and review of the literature. Clinical Case Reports (discontinued), 2016, 4, 1138-1146.	0.5	7
162	Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)―multicenter study. Annals of Hematology, 2016, 95, 1059-1065.	1.8	7

#	Article	IF	CITATIONS
163	Longitudinal detection of <i>DNMT3A</i> ^{R882H} transcripts in patients with acute myeloid leukemia. American Journal of Hematology, 2018, 93, E120-E123.	4.1	7
164	DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019065.	1.3	7
165	Nextâ€generation sequencing for BCRâ€ABL1 kinase domain mutations in adult patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia: A position paper. Cancer Medicine, 2020, 9, 2960-2970.	2.8	7
166	Role of Human Leukocyte Interferon-α in the Treatment of Patients With Polycythemia Vera. American Journal of the Medical Sciences, 1998, 315, 237-241.	1.1	7
167	Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial. Haematologica, 2022, 107, 2823-2833.	3.5	7
168	Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation. The Hematology Journal, 2004, 5, 24-31.	1.4	6
169	Detection and management of acute myeloid leukemia measurable residual disease. Current Opinion in Hematology, 2020, 27, 81-87.	2.5	6
170	Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML). Blood, 2020, 136, 37-38.	1.4	6
171	Increased levels of circulating interleukin-6 in patients with newly diagnosed non-Hodgkin's lymphomas. American Journal of Hematology, 1994, 46, 160-161.	4.1	5
172	First report of t(8;21)(q22;q22) in a case of de novo acute monoblastic leukemia. Cancer Genetics and Cytogenetics, 1995, 79, 82-85.	1.0	5
173	Low-dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial. Haematologica, 2017, 102, e47-e51.	3.5	5
174	An evaluation of enasidenib for the treatment of acute myeloid leukemia. Expert Opinion on Pharmacotherapy, 2019, 20, 1935-1942.	1.8	5
175	Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy. Blood, 2020, 136, 23-24.	1.4	5
176	Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia. Minerva Medica, 2020, 111, 386-394.	0.9	5
177	Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia. Expert Review of Anticancer Therapy, 2006, 6, 1787-1800.	2.4	4
178	Advances in the treatment of elderly and frail patients with acute myeloid leukemia. Current Opinion in Oncology, 2014, 26, 663-669.	2.4	4
179	Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials. Annals of Hematology, 2018, 97, 1785-1795.	1.8	4
180	Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial. Blood, 2014, 124, 3675-3675.	1.4	4

#	Article	IF	CITATIONS
181	<i>Pneumocystis jirovecii</i> pneumonia in patients with previously untreated acute myeloid leukaemia. Mycoses, 2022, 65, 233-238.	4.0	4
182	Vitamin C Deficiency in Patients With Acute Myeloid Leukemia. Frontiers in Oncology, 0, 12, .	2.8	4
183	A Novel t(11;12)(q23–24;q24) in a Case of Minimally-Differentiated Acute Myeloid Leukemia (AML-M0). Cancer Genetics and Cytogenetics, 2000, 118, 76-79.	1.0	3
184	TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013032.	1.3	3
185	Voriconazole treatment in adults and children with hematological diseases: can it be used without measurement of plasma concentration?. Medical Mycology, 2018, 56, 263-278.	0.7	3
186	Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation. Cancers, 2021, 13, 1083.	3.7	3
187	A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC). Blood, 2019, 134, 2652-2652.	1.4	3
188	MEN1112/OBT357, an Anti Bst1/CD157 Humanized Antibody Inducing Acute Myelogenous Leukemia (AML) Blast Depletion in an Autologous Ex Vivo Assay: A Potential New Targeted Therapy for AML. Blood, 2015, 126, 788-788.	1.4	3
189	A phase 3, randomized study of pracinostat (PRAN) in combination with azacitidine (AZA) versus placebo in patients ≥18 years with newly diagnosed acute myeloid leukemia (AML) unfit for standard induction chemotherapy (IC) Journal of Clinical Oncology, 2018, 36, TPS7078-TPS7078.	1.6	3
190	The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 4397-4397.	1.4	3
191	ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol. Blood Advances, 2022, 6, 2510-2516.	5.2	3
192	Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia. Leukemia and Lymphoma, 2009, 50, 857-858.	1.3	2
193	Clinical Significance of Apoptosis Is Independent from Proliferation in Acute Myeloid Leukemia (AML) Blood, 2004, 104, 198-198.	1.4	2
194	Variable Outcome of Allogeneic Stem Cell Transplant According to the Different Levels of Pre-Transplant Minimal Residual Disease, in Adult Patients with Acute Myeloid Leukemia. Blood, 2015, 126, 3230-3230.	1.4	2
195	Editorial: Metabolic Rewiring in Leukemias. Frontiers in Oncology, 2021, 11, 775167.	2.8	2
196	The Amount of Spontaneous Apoptosis Is An Independent Strong Disease Progression Indicator in B-Cell Chronic Lymphocytic Leukemia (B-CLL). Blood, 2009, 114, 1252-1252.	1.4	2
197	Validation of SIE, Sies, GITMO Operational Criteria for the Definition of Fitness in Elderly Patients Affected with Acute Myeloid Leukemia: A Six-Years Retrospective Real-Life Experience. Blood, 2019, 134, 2150-2150.	1.4	2
198	Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey. Frontiers in Oncology, 2022, 12, 828072.	2.8	2

#	Article	IF	CITATIONS
199	Occult central nervous system involvement guides therapeutic choices in blastic plasmacytoid dendritic cell neoplasms. Leukemia and Lymphoma, 2022, 63, 1754-1757.	1.3	2
200	CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML. Leukemia, 2022, , .	7.2	2
201	Leukocyte Alkaline Phosphatase Score in Plasma Cell Dyscrasias: Correlation with Disease Severity and Circulating Levels of Granulocyte-Colony Stimulating Factor. Leukemia and Lymphoma, 1995, 17, 479-483.	1.3	1
202	Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors. BMJ Supportive and Palliative Care, 2023, 13, e344-e351.	1.6	1
203	Biological Response Modifiers and Differentiating Agents in Myelodisplastic Syndromes. , 1993, , 171-177.		1
204	Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid Leukemia. Blood, 2019, 134, 2688-2688.	1.4	1
205	Fulminant B Hepatitis in a Hepatitis B Surface Antigen-Negative Patient after Rituximab Therapy for B-CLL Blood, 2005, 106, 5025-5025.	1.4	1
206	Genomic Aberrations Dramatically Improve The Strong Prognostic Impact Of IGHV Mutational Status In Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 1370-1370.	1.4	1
207	"ARMY": First-in-human study of the humanized, defucosylated monoclonal antibody (mAb) MEN1112/OBT357 targeting CD157 antigen, in relapsed or refractory (R/R) acute myeloid leukemia (AML) Journal of Clinical Oncology, 2015, 33, TPS3100-TPS3100.	1.6	1
208	Addition of Rituximab to Fludarabine Improves Progression Free Survival in Untreated ZAP-70 Negative Chronic Lymphocytic Leukemia (CLL) Blood, 2004, 104, 477-477.	1.4	1
209	ZAP-70 Protein Retains Its Prognostic Significance within Interphase Cytogenetic Groups in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Blood, 2004, 104, 2806-2806.	1.4	1
210	Epidemiology of Fungemia in Hematological Malignancies: Preliminary Report of Seifem-2015 Survey. Blood, 2015, 126, 4887-4887.	1.4	1
211	Mutational Profile of Leukemic Stem Cells in FLT3-ITD Mutated AML. Blood, 2019, 134, 1458-1458.	1.4	1
212	Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology?. Translational Pediatrics, 2013, 2, 43-5.	1.2	1
213	CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia. Leukemia and Lymphoma, 2021, , 1-5.	1.3	1
214	In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia. Journal of Clinical Medicine, 2022, 11, 1776.	2.4	1
215	Automated Haematology Analysers in Acute and Chronic Leukaemias. Acta Haematologica, 1998, 100, 61-62.	1.4	0
216	P116 Azacitidine for the treatment of lower risk myelodysplastic syndromes: final results from an Italian named patient program. Leukemia Research, 2009, 33, S127.	0.8	0

#	Article	IF	CITATIONS
217	Rituximab single agent in age-related Epstein–Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia. Annals of Hematology, 2014, 93, 1611-1612.	1.8	0
218	Health technology assessment–based approach to flow cytometric immunophenotyping of acute leukemias: a literature classification. Tumori, 2020, 106, 249-256.	1.1	0
219	Management of patients with acute myeloid leukemia undergoing therapy with midostaurin: a focus on antifungal prophylaxis. Hematological Oncology, 2021, 39, 20-26.	1.7	0
220	Future Developments: Measurable Residual Disease. Hematologic Malignancies, 2021, , 317-337.	0.2	0
221	Ponatinib and Risk of Thrombotic Events: In Vitro Study on Platelet Functions. , 2021, 7, 1-8.		0
222	AMELIORATE: early intensification in <i>FLT3</i> -mutated acute myeloid leukemia based on peripheral blast clearance –ÂMYNERVA-GIMEMA AML1919 trial. Future Oncology, 2021, 17, 3787-3796.	2.4	0
223	Prevalence and Genotyping of PneumocystisÂjirovecii Pneumonia in Patients with Previously Untreated Acute Myeloid Leukemia. Biology and Life Sciences Forum, 2021, 5, 3.	0.6	0
224	The Kinetic of Reduction of Minimal Residual Disease Impacts on duration of Response snd Survival of Patients with Acute Myeloid Leukemia Blood, 2004, 104, 399-399.	1.4	0
225	AML-M4: Role of Eosinophilia and Cytogenetics on Treatment Response and Survival. The GIMEMA Experience Blood, 2005, 106, 4501-4501.	1.4	0
226	Flow-Cytometric Minimal Residual Disease Determination Is a Surrogate Prognosticator in Adult AML Patients Lacking Specific Molecular Signatures Blood, 2007, 110, 3498-3498.	1.4	0
227	Complete Remission Achievement during Long-Term Maintenance with Bortezomib Based Therapy in Multiple Myeloma: A Case Report Blood, 2007, 110, 4815-4815.	1.4	0
228	5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program. Blood, 2008, 112, 2680-2680.	1.4	0
229	Acute Erythroid Leukemia: A Distinctive Subtype of AML? Outcome and Prognostic Factors in Comparison with Non-M6 AML. The Gimema Experience Blood, 2009, 114, 1019-1019.	1.4	0
230	MRD-Directed Post-Remissional Therapy Dramatically Improves Outcome of Adult Patients with High Risk AML by Implementing Allogeneic Transplant Option. Blood, 2010, 116, 2702-2702.	1.4	0
231	Clinical Significance of CD69 Expression In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 3574-3574.	1.4	0
232	Normal Fish Cytogenetics and 13q Deletions Unveil Marked Biological and Clinical Heterogeneity In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 2692-2692.	1.4	0
233	Clinical Significance of 13q14 Number of Deleted Cells in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 4581-4581.	1.4	0
234	Intensive Chemotherapy Does Not Prolong Survival Compared to 5-Azacitidine in Patients Aged 70 Years or More with Untreated Acute Myeloid Leukemia. Blood, 2012, 120, 3596-3596.	1.4	0

#	Article	IF	CITATIONS
235	Biological Pattern of AML-M0 Versus AML-M1: Response. Blood, 1997, 89, 345-345.	1.4	Ο
236	Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry. Blood, 2014, 124, 3265-3265.	1.4	0
237	Allogeneic but Not Autologous Stem Cell Transplant Attenuates the Negative Prognostic Impact Dictated By Pretransplant MRD Positivity. Blood, 2014, 124, 2363-2363.	1.4	Ο
238	Invasive Fungal Infections in Acute Promyelocytic Leukemia Patients. Results of a Prospective Multicenter Study in Italy. Blood, 2014, 124, 3682-3682.	1.4	0
239	Abstract 4050: Association of long term NK cell culture and TIMP3 over-expression with NK cell reduced susceptibility to leukemia and epithelial cancer cell induced damage. , 2015, , .		0
240	Apoptosis and Proliferation Synergistically Determine Overall Survival in Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 1718-1718.	1.4	0
241	Low Bax/Bcl-2 Ratio and NOTCH1 Mutations Represent Powerful and Synergistic Adverse Prognostic Factors within Trisomy 12 Chronic Lymphocytic Leukemia (CLL). Blood, 2016, 128, 3204-3204.	1.4	Ο
242	Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials. Blood, 2016, 128, 2847-2847.	1.4	0
243	Pattern of Central Nervous System (CNS) Involvement in Adult Acute Myeloid Leukemia (AML) and Its Impact on Outcome. Blood, 2016, 128, 2789-2789.	1.4	Ο
244	Early Intracranial Hemorrhages in Acute Promyelocytic Leukemia: Analysis of Neuroradiological and Clinico-Biological Parameters. Blood, 2019, 134, 5170-5170.	1.4	0
245	Multiparametric Flow-Cytometry Is a Reliable Tool for Measurable Residual Disease Assessment and Risk-Stratification of FLT3-Mutated AML Patients. Blood, 2019, 134, 5083-5083.	1.4	Ο
246	Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol. Blood, 2020, 136, 34-35.	1.4	0
247	Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol. Cancers, 2022, 14, 3012.	3.7	0